The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
Jevtana: new option for metastatic prostate cancer | MIMS online
Cabazitaxel for the treatment of castration-resistant prostate cancer | Future Oncology
a Progression-free survival of 63 Japanese patients with... | Download Scientific Diagram
Early serum and hematological variables recorded after 3 cycles of... | Download Scientific Diagram
Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
1415-Prostate metastatic cabazitaxel three weekly and prednisolone | eviQ
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance | BMC Cancer | Full Text
ASCO 2018: Cabazitaxel in mCRPC: Real-life Use, Effectiveness, Safety, and Quality of Life in the FUJI Cohort
Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel | Anticancer Research
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial - European Urology
Progression-free survival (PFS) after cabazitaxel treatment. a PFS in... | Download Scientific Diagram
Kaplan–Meier curves of overall survival by treatment group (TROPIC... | Download Scientific Diagram
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
ASCO GU 2021: Cabazitaxel Multiple Rechallenge in Metastatic Castration-Resistant Prostate Cancer: A Therapeutic Option to Increase Overall Survival?
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram
